SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Phase 3 DeFi Trial Evaluating... | May 3, 2023
United States Saqib Islam Samantha Hilson Sandler Trademark Office Springworks Therapeutics Inc Development Rd Expenses
Source: marketscreener.com